增值税降率对企业绩效与投资行为的影响研究——兼论增值税降率微观传导过程中的企业异质性问题

流转税的"税负转嫁"特征和现实企业的"议价能力"使理论上完全价外中性的增值税变为现实中的价内非中性,导致增值税降率微观传导机制"黑箱"。文章利用2015-2019年分行业上市公司的财务数据,采用双重差分模型实证检验了2018年增值税降率政策对企业投资行为、研发行为和制度性交易成本产生的影响。实证结果表明,现实中的增值税是价内非中性而非理论上的完全价外中性;降率的"抵扣冲减效应"对固定资产投资的直接负向作用显著,而降率的"收入效应"对固定资产投资的间接正向作用却不显著,最终降率政策"抵扣冲减效应"大于"收入效应"减少了固定资产投资;降率显著促进了"强势企业"的研发行为,对"弱势企业"无显著促进作用;降率节约了管理性交易成本的同时却导致政治性交易成本增加。妥善处理好增值税降率微观传导过程中的企业异质性问题,尤其是保护好降率过程中可能受损的中小企业是落实好普惠性减税的关键。     

The economic burden of tuberous sclerosis complex in UK patients with renal manifestations: a retrospective cohort study in the clinical practice research datalink (CPRD)

Background: Tuberous sclerosis complex (TSC) is a multi-system genetic disorder in which renal manifestations occur in ～50% of children and 80% of adults. Since these often present alongside other manifestations, renal TSC is likely to incur significant costs. This study aims to quantify healthcare resource use (HCRU) and costs for renal TSC patients in the UK.

Methods: TSC patients in the Clinical Practice Research Datalink (CPRD) linked to Hospital Episodes Statistics were identified from January 1987–June 2013. Clinical data were extracted over the entire history and costs were reported over the most recent 3-year period. HCRU was compared with a matched comparator cohort. Incremental costs were reported and the key cost drivers by primary manifestation category were identified by regression modeling.

Results: A total of 79 renal TSC patients were identified with manifestations including chronic kidney disease stage 3–5 (with prevalence increasing with age) and renal angiomyolipoma. Renal TSC patients consistently reported greater HCRU than the comparator. Inpatient hospitalizations were more frequent for renal TSC patients (3.2 vs 1.6), but length of stay was comparable; however, 70.9% of renal TSC patients recorded no kidney-related procedures ever and averaged <1 test per year in the 3-year period. Average costs for renal TSC patients were nearly 3-fold greater than the comparator (£15,162 vs £5672). Costs increased with additional manifestation categories (£3600: only renal; £27,531: renal with ≥4 additional manifestation categories [25% of patients]). Additional nervous system and dermatology/psychiatric manifestations significantly (p?Conclusions: Renal TSC patients have greater HCRU than the general CPRD population, likely to result from progression of renal disease and additional manifestations; however, surveillance for disease progression appears to be deficient. Inadequate monitoring may contribute to a lack of co-ordinated care and increased healthcare-associated costs. Efforts should be made to follow the TSC guidelines to effectively monitor and treat patients.     

地方公共服务、要素流动与要素空间配置——基于本地交易成本的均衡分析

通过"两区域、两要素与两部门"模型研究发现,即使存在区域内与区域间两类交易成本,增加公共服务仍有利于吸引要素流入,并产生要素空间聚集效应;增加公共支出以改善区内贸易条件对要素流动及其空间分布具有不同的影响;我国地方公共支出规模与全要素生产率之间存在明显的长期因果关系.     

产业集群外部性的产权问题探析

本文将立足于集群经济的外部性进行考察,运用产权理论的内生交易费用和外生交易费用理论对其进行分析和初步研究探讨。产权清晰性或是模糊性的设定和安排的本质是一个费用问题,由于内生交易费用与外生交易费用的两难冲突,只有内生费用和外生费用的总和最小时,才是有效率的。最后,提出了产业集群的发展在清晰产权和模糊产权这两种制度安排的选择问题。     

对国际卡特尔的有效惩罚额度研究

对国际卡特尔行为实施有效威慑的一个关键问题是如何确立惩罚额度。本文认为，无论是以美国为代表的3倍损失赔偿，还是以欧盟为代表的单倍损失赔偿，都不是合理的惩罚标准。对国际卡特尔的合理的惩罚额度应使卡特尔成员承担其非法行为所带来的全部社会成本，包括国际卡特尔的超高定价、社会净损失、调查诉讼成本以及监禁成本。     

To Bundle or Not to Bundle: Firms’ Choices under Pure Bundling

We examine the economic implications of pure bundling under the settings of monopoly and duopoly. We show that under monopoly and pure bundling of goods with independent demands, the bundled price is strictly less than the sum of the unbundled prices. In the setting of duopoly and Nash prices, we examine whether bundling can be used as a tool to deter entry. In contrast to the findings of previous studies, we show that with low entry costs, entry is deterred by unbundled as opposed to bundled sales. With high entry costs, however, the incumbent chooses to bundle.     

论国有商业银行的双重功能与不良资产的双重成因

国有商业银行所形成的巨额不良资产，需要从其事实上履行的双重功能入手进行解析：国有商业银行在履行基本功能时，由于行业性风险产生的不良资产具有普遍性和内生性；但其在履行公共性功能时。由于承担的政策性风险和支付的履职成本无法分摊导致的超额不良资产，具有特殊性和外生性。因此。降低国有商业银行的不良资产，既要控制行业性风险，更要建立对其履行特殊功能所支付成本的合理分摊机制，并随着市场机制作用的增强从体制上逐步淡化其特殊功能，从根本上解决由外生性原因造成的超额不良资产。     

Adalimumab,etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients

Abstract

Objectives:

To evaluate the utilization patterns of the anti-tumor necrosis factor (anti-TNF) agents Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab) in patients with rheumatoid arthritis (RA) and compare medication costs during the first year of treatment. (Humira is a registered trademark of Abbott Laboratories, IL; Enbrel is a registered trademark of Immunex Corporation, CA; and Remicade is a registered trademark of Janssen Biotech, Inc., PA).

Methods:

This retrospective analysis of medical and pharmacy claims included patients who were aged ≥18 years, had ≥2 RA diagnosis codes, and had ≥365 days of persistence with the index anti-TNF. Patients excluded had claims for anti-TNF agents within 6 months before the index date. Refill patterns for adalimumab and etanercept, number of infliximab infusions, time between infusions, and dose per infusion were analyzed for 12 months. Direct anti-TNF medication costs were compared among anti-TNFs for the initial treatment year.

Results:

Infliximab-treated patients (n?=?457) were significantly older than adalimumab- (n?=?337) or etanercept-treated patients (n?=?902). Time between refills was longer than recommended for 28% and 30% of adalimumab and etanercept refill periods, respectively. Potential cumulative time without therapy was 33 days for adalimumab and 43 days for etanercept. Statistically significant differences in mean per-patient anti-TNF medication costs for the first year were reported for adalimumab, etanercept, and infliximab ($14,991, $13,361, and $18,139, respectively; p?<?0.0001); however, a cost assessment using labeled dosing of the anti-TNF agents with optimal treatment compliance yielded comparable annual medication costs.

Limitations:

This analysis only evaluated utilization patterns for selected anti-TNF agents and was not inclusive of other medications that patients may have been using for RA. Absolute patient adherence could not be assessed due to lack of information on how patients were self-administering adalimumab and etanercept or if samples of the agents were made available.

Conclusions:

This study identified gaps in patients’ refills compared with prescriber recommendations. The infliximab-treated group had infusion patterns consistent with prescribing information. Potential clinical and economic implications of dose attenuation with adalimumab and etanercept should be explored further.     

Larger crises cost more: Impact of banking sector instability on output growth

We propose a method for calculating the macroeconomic costs of banking crises that controls for the downward impact of recessions on banking activity. This method uses an event-study approach and a multiple-equation identification and estimation technique. In contrast to earlier research, we estimate the cost of crises based on the size of banking crises. The extent of a crisis is measured using banking sector aggregates. The results, based on our method and data from over 100 banking crises, suggest that it is the size of the crisis that matters for economic growth. Lower credit and money growth during crises cause GDP growth to decline.